With a core competence in the field of healthcare, Zydus Cadila provides total healthcare solutions ranging from formulations, active pharmaceutical ingredients and animal healthcare products to wellness products. Zydus is the only Indian pharma company to launch its own patented NCE – Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia. . The group’s origin can be traced to 1952 when it was founded by Late Mr. Ramanbhai B. Patel, a first-generation entrepreneur and one of the stalwarts of the Indian Pharmaceutical Industry. In 1995, the group restructured its operations and Cadila Healthcare came into being under the aegis of the Zydus group. Zydus Cadila, today, is spearheaded by Mr. Pankaj R. Patel, the Chairman and Managing Director of the group. From a turnover of Rs. 250 crores in 1995, the group posted revenues of Rs. 6300 crores in FY13. The group had posted a turnover of Rs. 4600 crores in FY 11, making it a billion dollar company. The group was declared as the ‘Emerging Company of the Year’ by the Economic Times Awards for Corporate Excellence 2010. In January 2014, Mr. Pankaj Patel was conferred the India Innovator Award 2013 at the India Business Leaders Awards instituted by CNBC. The group employs over 16,000 people worldwide including over 1100 Scientists engaged in R & D and is dedicated in creating healthier communities globally. As a leading healthcare provider, it aims to become a Global Research based Pharmaceutical Company by 2020. The group has a strong Research Pipeline of NCEs, Biologics and Vaccines which are in various stages of clinical trials including late stage.
